NFKB1 and neoplasm: Because NF-κB is essential for normal immune function, broad inhibition carries significant toxicity risks; therefore, current strategies emphasize selective targeting of dysregulated NF-κB subunits or context-specific modulation within tumor cells versus immune cells.